Track record · closed signal

Pfizer Inc (PFE) — closed signal from April 16, 2026

Partial Published before the outcome was known, scored automatically when the window closed on July 15, 2026 — -9.2% at the close.

Predicted vs. what happened

PFE price · publication thesis → realized outcomesplit-adjusted

$26.80 – $27.60Entry zone — fair-value band

$27.34Published — price the day we called it

$29.52Target — the price the thesis aimed for

$27.85Peak — highest point inside the window, not a realized return

$24.82Window close — end-of-window price, context only

What happened

Partial

Reached 24% of the predicted growth at its peak, without hitting the target.

At window close

-9.2%

realized, from the publication price to the last close inside the window

Peak gain

+1.9%

peak, from the publication price — not a realized return

S&P 500, same window

+7.9%

SPY over the identical days, dividend-adjusted

Window close

$24.82

last close inside the window, ended July 15, 2026

Peak price

$27.85

peak on April 20, 2026 — not a realized return

Days to target

—

The thesis — published April 16, 2026

Predicted growth

+8%

over the measurement window

Target price

$29.52

the price the thesis aimed for

Entry zone

$26.80 – $27.60

the fair-value band we waited for

Price at publication

$27.34

published April 16, 2026

Confidence

67%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Pfizer is not showing strong growth, but with low expectations and a calmer stock price there is a chance for a short-term rebound over the next quarter. Recent analyst notes and a small target increase slightly improved sentiment. If quarterly results show the business stabilizing, the rebound case gains credibility; weak core growth keeps confidence limited.

Primary drivers

Earnings will show if revenue and profit are steady or improving
A small target increase has slightly improved investor mood
A diverse drug and vaccine portfolio gives defensive stability
Share price has pulled back enough to allow a tactical bounce

How it played out

PFE: the short-term rebound thesis missed

Lyra published a short-term rebound thesis for PFE. It expected 8% growth from 27.34. The thesis pointed to quarterly results as a test of stability, a small analyst target increase, defensive support from a diverse drug and vaccine portfolio, and room for a tactical bounce after the pullback.

PFE peaked at 27.85 on April 20, a 1.9% gain. That stayed below 29.52, and the target was never reached. By July 15, the stock had fallen to 24.82. The published rebound thesis missed.

What happened during the window

On April 28, Pfizer said it had reached settlement agreements with three generic manufacturers over VYNDAMAX patent litigation. On May 28, Pfizer announced a global oncology licensing and collaboration agreement with Innovent covering 12 programs.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All PFE signals